Due to the decrease in the activity of microsomal oxidation in hepatocytes, it increases the concentration and prolongs the half-life of theophylline (and other xanthines, for example, caffeine), oral hypoglycemic drugs, indirect anticoagulants, and helps to reduce the prothrombin index.At simultaneous admission with theophylline it is recommended to conduct a constant control of the concentration of theophylline in the blood plasma and, if necessary, reduce the dose of theophylline.
When combined with other antimicrobial drugs (beta-lactam antibiotics, aminoglycosides, clindamycin, metronidazole) synergy is usually observed; can be successfully used in combination with azlocillin and ceftazidime in infections caused by Pseudomonas spp .; with mezlocillin, azlocillin, etc. beta-lactam antibiotics - with streptococcal infections; with isoxazolylpenicillins and vancomycin - with staphylococcal infections; with metronidazole and clindamycin - with anaerobic infections.
Increases the nephrotoxic effect of cyclosporine, there is an increase in serum creatinine, in such patients monitoring of this indicator is required 2 times a week.
With simultaneous admission with indirect anticoagulants, it is often necessary to monitor the international normalized relationship, as well as within a short time after the completion of the combination therapy. Oral reception together with iron-containing drugs,sucralfate and antacid medicines containing magnesium, calcium and aluminum salts, leads to a decrease in absorption of ciprofloxacin, so it should be prescribed 1-2 hours before or 4 hours after the administration of the above medicines.
The simultaneous use of ciprofloxacin and dairy products or beverages enriched with minerals (eg milk, yogurt, calcium-fortified orange juice) should be avoided, since the absorption of ciprofloxacin may decrease. However, calcium, which is part of other foods, does not significantly affect the absorption of ciprofloxacin.
Non-steroidal anti-inflammatory drugs (excluding acetylsalicylic acid) increase the risk of seizures. Fluoroquinolones form chelate compounds with magnesium and aluminum ions of the didanosine dosage form buffer system, which drastically reduces the absorption of antibiotics, therefore ciprofloxacin take 2 hours before taking didanosine or 2 hours after taking this medication.
Metoclopramide accelerates absorption, which leads to a decrease in the time to reach its maximum concentration.
Ciprofloxacin, due to a decrease in the activity of microsomal oxidation in hepatocytes, increases the plasma concentration and extends T1 / 2 glibenclamide, which can lead to hypoglycemia, in rare cases, severe. Simultaneous use of ciprofloxacin with glibenclamide can enhance the effect of the latter.
With the simultaneous use of ciprofloxacin and phenytoin, there was a change (increase or decrease) in the content of phenytoin in the blood plasma. In order to avoid weakening of the anticonvulsant effect of phenytoin due to a decrease in its concentration, and also to prevent undesirable phenomena associated with a phenytoin overdose when ciprofloxacin is discontinued, it is recommended to monitor phenytoin therapy in patients taking both drugs. including the determination of the content of phenytoin in the blood plasma during the entire period of simultaneous application of both drugs and for a short time after the completion of the combination therapy. Caution should be exercised while using ciprofloxacin, as well as other fluoroquinolones, in patients receiving drugs that cause prolongation of the QT interval (for example, antiarrhythmic drugs of Class 1A or Class III.tricyclic antidepressants, macrolides, antipsychotics) (see section "Special instructions").
The combined use of uricosuric drugs leads to slower elimination (50%) and increase plasma concentration of ciprofloxacin. Increases in the maximum concentration of 7 times (4 to 21 times) and the area under the curve "concentration-time" 10 times (from 6 to 24 times) tizanidine, which exceeds the risk of significant decrease in blood pressure and sleepiness.
With simultaneous use with omeprazole, there may be a slight decrease in the maximum plasma concentration in the plasma and a decrease in AUC.
Probenecid inhibits the excretion of ciprofloxacin by the kidneys, leading to an increase in the concentration of ciprofloxacin.
In a study on healthy volunteers, it was found that the simultaneous use of drugs containing lidocaineAnd ciprofloxacin, a moderate inhibitor of isozyme CYP1A2 reduces the lidocaine clearance by 22% when administered intravenously. In spite of the good tolerability of lidocaine, simultaneous application with ciprofloxacin may increase the side affects due to the interaction.
With the simultaneous use of clozapine and ciprofloxacin at a dose of 250 mg for 7 days, there was an increase in serum concentrations of clozapine and N-desmethylclozapine by 29% and 31%, respectively. It is necessary to monitor the patient's condition and, if necessary, adjust the dosage regimen of clozapine during its simultaneous use with ciprofloxacin and for a short time after the completion of the combination therapy.
With the simultaneous use of ciprofloxacin and methotrexate, the renal tubular methotrexate transport slows, potentially leading to increased plasma concentrations of methotrexate, which may increase the risk of toxic reactions associated with methotrexate. Therefore, it is necessary to monitor the condition of patients in the treatment of methotrexate and simultaneous administration of ciprofloxacin.
Clinical studies have shown that the simultaneous use of duloxetine and potent inhibitors of the CYP1A2 isoenzyme (such as fluvoxamine) can lead to an increase in AUC and Cmax duloxetine. Despite the lack of clinical data on the possible interaction with ciprofloxacin,it is possible to predict the likelihood of such interaction with the simultaneous use of ciprofloxacin and duloxetine.
With the simultaneous use of ropinirole with ciprofloxacin, there is a possibility of an increase in the concentration of ropinirole, which may be accompanied by an increased risk of unwanted reactions. In case of simultaneous application it is necessary to control the adverse effects of ropinirole during its simultaneous application with ciprofloxacin and for a short time after completion of the combination therapy.
With the simultaneous use of ciprofloxacin in a dose of 500 mg and sildenafil at a dose of 50 mg, there was an increase in Cmax and AUC sildenafil in 2 times. The use of this combination is only possible after an evaluation of the benefit / risk ratio.